Home Cart Sign in  
Chemical Structure| 1380336-17-3 Chemical Structure| 1380336-17-3

Structure of TIQ-15
CAS No.: 1380336-17-3

Chemical Structure| 1380336-17-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Piyapan Suwattananuruk ; Sukanya Yaset ; Chanisa Chotipanich ; Angel Moldes-Anaya ; Rune Sundset ; Rodrigo Berzaghi , et al.

Abstract: Background: This study aimed to develop a novel positron emission tomography (PET) tracer, [68Ga]Ga-TD-01, for CXCR4 imaging. To achieve this goal, the molecular scafold of TIQ15 was tuned by conjugation with the DOTA chelator to make it suitable for 68Ga radiolabeling. Methods: A bifunctional chelator was prepared by conjugating the amine group of TIQ15 with p-NCS-Bz-DOTA, yielding TD-01, with a high yield (68.92%). TD-01 was then radiolabeled with 68Ga using 0.1 M ammonium acetate at 60 °C for 10 min. A 1-h dynamic small animal PET/MRI study of the labeled compound in GL261-luc2 tumor-bearing mice was performed, and brain tumor uptake was assessed. Blocking studies involved pre-administration of TIQ15 (10 mg/kg) 10 min before the PET proce-dure started. Results: [68Ga]Ga-TD-01 exhibited a radiochemical yield (RCY) of 36.33±1.50% (EOS), with a radiochemical purity >99% and a molar activity of 55.79±1.96 GBq/µmol (EOS). The radiotracer showed in vitro stability in PBS and human plasma for over 4 h. Biodistribution studies in healthy animals revealed favorable kinetics for subsequent PET pharmacokinetic modeling with low uptake in the brain and moderate uptake in lungs, intestines and spleen. Elimination could be assigned to a renal-hepatic pathway as showed by high uptake in kidneys, liver, and urinary bladder. Importantly, [68Ga]Ga-TD-01 uptake in glioblastoma (GBM)-bearing mice signifcantly decreased upon competition with TIQ15, with a baseline tumor-to-background ratios >2.5 (20 min p.i.), indicating high specifcity. Conclusion: The newly developed CXCR4 PET tracer, [68Ga]Ga-TD-01, exhibited a high binding inhibition for CXCR4, excellent in vitro stability, and favorable phar‑macokinetics, suggesting that the compound is a promising candidate for full in vivo characterization of CXCR4 expression in GBM, with potential for further development as a tool in cancer diagnosis.

Keywords: CXCR4 receptor ; Glioblastoma (GBM) ; 68Ga ; Bifunctional chelator (BFC) ; Positron emission tomography ; PET tracer

Purchased from AmBeed: ;

Alternative Products

Product Details of TIQ-15

CAS No. :1380336-17-3
Formula : C23H32N4
M.W : 364.53
SMILES Code : NCCCCN(C[C@@H]1NCC2=C(C=CC=C2)C1)[C@H]3CCCC4=C3N=CC=C4
MDL No. :N/A

Safety of TIQ-15

Related Pathways of TIQ-15

GPCR

Isoform Comparison

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.74mL

0.55mL

0.27mL

13.72mL

2.74mL

1.37mL

27.43mL

5.49mL

2.74mL

 

Historical Records

Categories